Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food effect on BI 1015550 pharmacokinetics in healthy subjects
NCT06415045Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nerandomilast (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point at 144 hours and Maximum Measured Concentration of Nerandomilast in Plasma at 144 hours. Started May 2024; status: completed.
02
Drugs
nerandomilast
Beyond the preview
Go deeper on NCT06415045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06415045.